TP53TG3

Summary

TP53TG3 (TP53 target 3, HGNC:30759) is a protein-coding gene on chromosome 16p11.2, encoding TP53-target gene 3 protein (Q9ULZ0). May play a significant role in p53/TP53-mediating signaling pathway.

Located in cytoplasm and nucleus.

Source: NCBI Gene 24150 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 4 total
• MANE Select transcript: NM_016212

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30759
Approved symbol	TP53TG3
Name	TP53 target 3
Location	16p11.2
Locus type	gene with protein product
Status	Approved
Aliases	P53TG3, TP53TG3A
Ensembl gene	ENSG00000183632
Ensembl biotype	protein_coding
OMIM	617482
Entrez	24150

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 2 protein_coding, 2 retained_intron, 2 nonsense_mediated_decay, 2 protein_coding_CDS_not_defined

ENST00000398682, ENST00000562021, ENST00000563102, ENST00000563658, ENST00000564154, ENST00000565622, ENST00000568854, ENST00000569420

RefSeq mRNA: 1 — MANE Select: NM_016212 NM_016212

CCDS: CCDS45475

Canonical transcript exons

ENST00000398682 — 2 exons

Exon	Start	End
ENSE00003978306	32673530	32674564
ENSE00003978307	32675736	32676165

Expression profiles

Bgee: expression breadth broad, 94 present calls, max score 85.77.

Top tissues by expression

119 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	85.77	gold quality
testis	UBERON:0000473	81.90	gold quality
left testis	UBERON:0004533	81.90	gold quality
right testis	UBERON:0004534	81.71	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	75.03	gold quality
placenta	UBERON:0001987	63.22	gold quality
stromal cell of endometrium	CL:0002255	58.28	gold quality
monocyte	CL:0000576	54.31	gold quality
leukocyte	CL:0000738	52.97	gold quality
lower esophagus mucosa	UBERON:0035834	49.49	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	48.39	gold quality
cerebellum	UBERON:0002037	48.08	gold quality
cerebellar cortex	UBERON:0002129	47.80	gold quality
cerebellar hemisphere	UBERON:0002245	47.74	gold quality
right hemisphere of cerebellum	UBERON:0014890	46.96	gold quality
right coronary artery	UBERON:0001625	46.77	gold quality
ganglionic eminence	UBERON:0004023	44.95	gold quality
ventricular zone	UBERON:0003053	44.46	gold quality
Brodmann (1909) area 9	UBERON:0013540	43.38	gold quality
bone marrow cell	CL:0002092	42.90	gold quality
skeletal muscle tissue	UBERON:0001134	42.73	gold quality
heart left ventricle	UBERON:0002084	42.60	gold quality
primary visual cortex	UBERON:0002436	42.60	gold quality
prefrontal cortex	UBERON:0000451	41.77	gold quality
superior frontal gyrus	UBERON:0002661	41.53	gold quality
frontal cortex	UBERON:0001870	41.43	gold quality
right frontal lobe	UBERON:0002810	41.20	gold quality
bone marrow	UBERON:0002371	40.87	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	40.39	gold quality
descending thoracic aorta	UBERON:0002345	40.37	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.29

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): TP53

miRNA regulators (miRDB)

68 targeting TP53TG3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-539-5P	99.93	70.30	2855
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-380-3P	99.89	70.18	1978
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-12119	99.87	68.35	1653
HSA-MIR-6875-3P	99.82	70.26	2983
HSA-MIR-3180-5P	99.82	69.12	2422
HSA-MIR-8080	99.82	67.52	1342
HSA-MIR-4524A-3P	99.72	66.85	2406
HSA-MIR-3714	99.71	70.74	2671
HSA-MIR-4690-5P	99.65	66.24	813
HSA-MIR-6126	99.62	68.09	996
HSA-MIR-548AV-5P	99.60	70.84	2107
HSA-MIR-548K	99.60	70.84	2107
HSA-MIR-4649-3P	99.56	66.90	1783
HSA-MIR-1252-3P	99.55	67.71	2862
HSA-MIR-17-3P	99.55	66.77	1311
HSA-MIR-7159-5P	99.53	72.12	2472
HSA-MIR-8054	99.48	70.81	2084
HSA-MIR-5695	99.41	67.48	1047
HSA-MIR-4251	99.40	69.19	3363
HSA-MIR-148A-5P	99.30	68.27	1141

Cross-species orthologs

0 orthologs

Paralogs (7): TP53TG3D (ENSG00000205456), TP53TG3C (ENSG00000205457), TP53TG3B (ENSG00000261509), (ENSG00000274175), TP53TG3E (ENSG00000275034), (ENSG00000275869), TP53TG3F (ENSG00000278848)

Protein

Protein identifiers

TP53-target gene 3 protein — Q9ULZ0 (reviewed: Q9ULZ0)

Alternative names: TP53-inducible gene 3 protein

All UniProt accessions (2): Q9ULZ0, I3L219

UniProt curated annotations — full annotation on UniProt →

Function. May play a significant role in p53/TP53-mediating signaling pathway.

Subcellular location. Cytoplasm. Nucleus.

Tissue specificity. Strongly expressed in testis. Weakly expressed in heart, placenta and skeletal muscle.

Induction. By p53/TP53.

Miscellaneous. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9ULZ0-2	2, TP53TG3a	yes
Q9ULZ0-1	1, TP53TG3b
Q9ULZ0-3	3

RefSeq proteins (1): NP_057296* (*=MANE)

Domains & families (InterPro)

UniProt features (6 total): splice variant 3, chain 1, region of interest 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9ULZ0-F1	40.37	0.00

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 26 (showing top): WANG_CLIM2_TARGETS_UP, XU_HGF_TARGETS_REPRESSED_BY_AKT1_DN, chr16p11, WALLACE_PROSTATE_CANCER_RACE_DN, ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_DN, MIR3646, MIR548AW, MIR551B_5P, MIR3065_5P, MIR539_5P, MIR4291, MIR1252_3P, MIR4801, MIR4731_3P, MIR509_5P

GO Biological Process (0):

GO Molecular Function (0):

GO Cellular Component (2): nucleus (GO:0005634), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

268 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TP53TG3	TP53I11	O14683	400
TP53TG3	PGBD2	Q6P3X8	398
TP53TG3	GLYATL3	Q5SZD4	393
TP53TG3	ZNF672	Q499Z4	370
TP53TG3	TP53TG5	Q9Y2B4	352
TP53TG3	FAM174A	Q8TBP5	351
TP53TG3	ZNF595	Q8IYB9	348
TP53TG3	ZNF280A	P59817	325
TP53TG3	HEATR5B	Q9P2D3	324
TP53TG3	VSIG10	Q8N0Z9	323
TP53TG3	FAM72B	Q86X60	314
TP53TG3	DYDC2	Q96IM9	310
TP53TG3	SLC6A8	P48029	306
TP53TG3	TP53I13	Q8NBR0	305
TP53TG3	SMIM3	Q9BZL3	297

IntAct

1 interactions, top by confidence:

BioGRID (5): TP53TG3C (Negative Genetic), TP53TG3C (Negative Genetic), TP53TG3B (Negative Genetic), TP53TG3 (Positive Genetic), TP53TG3 (Affinity Capture-RNA)

ESM2 similar proteins: A0A1B0GUT2, A0A3Q1LFG5, A1L4Q6, A2RUQ5, A8MQB3, A8MU10, B1ANY3, C0HM98, H3BQW9, J3KSC0, P0C092, P0DMU3, P0DPA3, P24026, P59020, P59021, P59052, P87743, Q06250, Q0IIN9, Q0VFX4, Q14695, Q4R3X9, Q4VX62, Q52M75, Q5SR53, Q6ZUF6, Q6ZWC4, Q71F78, Q7Z4H9, Q8JMY5, Q8JMZ5, Q8JN06, Q8N2C9, Q8N2X6, Q8N3U1, Q8N9X3, Q8NAA6, Q8NBC4, Q8NDY4

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

4 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	0
Likely benign	0
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

363 predictions. Top by Δscore:

Variant	Effect	Δscore
16:32674897:G:C	donor_gain	0.9900
16:32674903:T:TA	donor_gain	0.9900
16:32674809:AGAC:A	donor_gain	0.9800
16:32675445:T:TA	donor_gain	0.9400
16:32675730:CGTTA:C	donor_loss	0.9400
16:32675731:GTTA:G	donor_loss	0.9400
16:32675731:GTTAC:G	donor_loss	0.9400
16:32675732:TTA:T	donor_loss	0.9400
16:32675733:TA:T	donor_loss	0.9400
16:32675734:A:AG	donor_loss	0.9400
16:32675734:A:AT	donor_loss	0.9400
16:32675735:C:CG	donor_loss	0.9400
16:32675735:C:CT	donor_loss	0.9400
16:32674908:A:AC	donor_gain	0.9300
16:32675736:C:G	donor_loss	0.9100
16:32674933:T:TA	donor_gain	0.8900
16:32675985:TCA:T	donor_gain	0.8900
16:32675738:TGACA:T	donor_gain	0.8800
16:32675463:C:CT	donor_gain	0.8700
16:32675729:GCGTT:G	donor_loss	0.8700
16:32674728:C:CT	donor_gain	0.8500
16:32674729:T:TT	donor_gain	0.8500
16:32675881:G:C	donor_gain	0.8300
16:32674566:T:C	acceptor_gain	0.8200
16:32674890:C:A	donor_gain	0.8100
16:32674560:AAAAA:A	acceptor_loss	0.8000
16:32674563:AACTT:A	acceptor_loss	0.8000
16:32674564:ACTTA:A	acceptor_loss	0.8000
16:32674563:AA:A	acceptor_gain	0.7900
16:32675349:C:CT	donor_gain	0.7900

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1012111496 (16:32677000 G>A,C), RS1021593997 (16:32677044 C>T), RS1029191503 (16:32676970 A>T), RS1035585912 (16:32677287 C>G), RS1036631996 (16:32676945 G>C), RS1158061216 (16:32677667 ATAT>A), RS1158318718 (16:32677046 A>G), RS1158642487 (16:32677784 G>T), RS1159526679 (16:32676551 C>A), RS1162806481 (16:32677066 T>G), RS1163616455 (16:32676592 G>A), RS1167168087 (16:32677238 A>G), RS1167325337 (16:32677349 T>C,G), RS1173238981 (16:32676884 A>G), RS1173393406 (16:32676736 AG>A)

Disease associations

OMIM: gene MIM:617482 | disease phenotypes: MIM:189800

GenCC curated gene-disease

Mondo (1): preeclampsia (MONDO:0005081)

Orphanet (1): Preeclampsia (Orphanet:275555)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011225	Pre-Eclampsia	C12.050.703.395.249

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

15 total (human), top 15 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
butyraldehyde	decreases expression	1
beta-methylcholine	affects expression	1
CGP 52608	affects binding, increases reaction	1
Grape Seed Proanthocyanidins	affects cotreatment, increases expression	1
Decitabine	affects expression	1
Arsenic Trioxide	increases expression	1
Catechin	affects cotreatment, increases expression	1
Cisplatin	affects expression	1
Diethylhexyl Phthalate	decreases expression	1
Silicon Dioxide	increases expression	1
Valproic Acid	decreases methylation	1
Aflatoxin B1	decreases methylation	1
Sodium Selenite	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00117546	PHASE4	UNKNOWN	Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia
NCT00567957	PHASE4	UNKNOWN	Remifentanil for General Anesthesia in Preeclamptics
NCT01030627	PHASE4	COMPLETED	Treatment Approaches to Preeclampsia
NCT01352234	PHASE4	COMPLETED	Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia
NCT01361425	PHASE4	UNKNOWN	Anti-Hypertensive Treatment In Stable Pregnant Women With Severe Pre-Eclampsia (Metildopape)
NCT01729468	PHASE4	COMPLETED	Prevention of Pre-eclampsia and SGA by Low-Dose Aspirin in Nulliparous Women With Abnormal First-trimester Uterine Artery Dopplers
NCT01761916	PHASE4	COMPLETED	Clonidine Versus Captopril for Treatment of Postpartum Very High Blood Pressure
NCT01912677	PHASE4	COMPLETED	Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy
NCT02025426	PHASE4	TERMINATED	Phenylephrine Versus Ephedrine in Pre-eclampsia
NCT02091401	PHASE4	COMPLETED	A Trial Comparing Treatment With the Springfusor Infusion Pump to the IV Magnesium Sulfate Regimen
NCT02163655	PHASE4	COMPLETED	Diuretics for Postpartum High Blood Pressure in Preeclampsia
NCT02338687	PHASE4	COMPLETED	Low Dose Calcium to Prevent Preeclampsia
NCT02396030	PHASE4	TERMINATED	Different Schemes of Magnesium Sulfate for Preeclampsia
NCT02531490	PHASE4	UNKNOWN	Early Vascular Adjustments During Hypertensive Pregnancy
NCT02699827	PHASE4	COMPLETED	Adding MgSO4 to Epidural Levobupivacaine in CS for Patients With Preeclampsia
NCT02835339	PHASE4	COMPLETED	Magnesium Sulfate in Obese Preeclamptics
NCT02891174	PHASE4	COMPLETED	The Effect of Ibuprofen on Post-partum Blood Pressure in Women With Hypertensive Disorders of Pregnancy
NCT02911701	PHASE4	COMPLETED	Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features
NCT03171480	PHASE4	COMPLETED	Use of Nitrous Oxide Donor for Labor Induction in Women With PreEclampsia
NCT03233880	PHASE4	UNKNOWN	Impact of Antichlamydial Treatment on the Rate of Preeclampsia
NCT03237000	PHASE4	UNKNOWN	Effect of Administering Intravenous Magnesium Sulfate on Fetal Cardiotocography and Neonatal Outcome in Preeclamptic Patients
NCT03506724	PHASE4	COMPLETED	Response to Anti-hypertensives in Pregnant and Postpartum Patients
NCT03674606	PHASE4	COMPLETED	Trial of Early Screening Test for Pre-eclampsia and Growth Restriction
NCT03735433	PHASE4	TERMINATED	The Effect of Two Aspirin Dosing Strategies for Obese Women at High Risk for Preeclampsia
NCT03824119	PHASE4	UNKNOWN	Postpartum NSAIDS and Maternal Hypertension
NCT04051567	PHASE4	UNKNOWN	Low-dose Aspirin for Prevention of Adverse Pregnancy Outcomes in Twin Pregnancies
NCT04077853	PHASE4	COMPLETED	Progesterone in Expectantly Managed Early-onset Preeclampsia
NCT04158830	PHASE4	WITHDRAWN	Aspirin (ASA) Therapy and Preeclampsia Prevention
NCT04424693	PHASE4	UNKNOWN	Comparing the Incidence of Preeclampsia Between Pregnant Women Receiving Tdap Vaccinations at Week 28 or at Week 36
NCT04631627	PHASE4	UNKNOWN	Early Prediction and Randomised Prevention of Preeclampsia With Low Dose Aspirin in Chinese Cohort
NCT04656665	PHASE4	UNKNOWN	The Effectiveness of Aspirin on Preventing Pre-eclampsia
NCT04797949	PHASE4	WITHDRAWN	Adherence to Universal Aspirin Compared to Screening Indicated Aspirin for Prevention of Preeclampsia
NCT04908982	PHASE4	UNKNOWN	Aspirin for the Prevention of Preeclampsia in Women With Stage 1 Hypertension
NCT05221164	PHASE4	UNKNOWN	162 mg of Aspirin for Prevention of Preeclampsia
NCT05294952	PHASE4	UNKNOWN	co Ihibtory Receptor in Preeclampsia
NCT05514847	PHASE4	ACTIVE_NOT_RECRUITING	Low Dose Aspirin for Preterm Preeclampsia Preventionmg/day Dose in High-risk Patients
NCT05586373	PHASE4	COMPLETED	Ibuprofen vs Dipyrone After C-section in Preeclampsia
NCT06069102	PHASE4	COMPLETED	Optimal Blood Pressure Treatment Thresholds Postpartum
NCT06107335	PHASE4	NOT_YET_RECRUITING	Effect of Albumin Versus Routine Care on Hemodynamic Response and Stability in Patients With Preeclampsia Guided by a Non-invasive Hemodynamic Monitoring System During Cesarean Delivery With Spinal Anesthesia
NCT06281665	PHASE4	RECRUITING	Treatment With Aspirin After Preeclampsia: TAP Trial